COMPARATIVE STUDIES ON ACTIVITIES OF ANTIMICROBIAL AGENTS AGAINST CAUSATIVE ORGANISMS ISOLATED FROM URINARY TRACT INFECTIONS (1986)

Bibliographic Information

Other Title
  • 尿路感染症分離抗菌に対する経口並びに注射用抗菌・抗生剤の抗菌力比較 (第8報1986年)
  • I. SUSCEPTIBILITY DISTRIBUTION
  • その1. 感受性について

Abstract

Susceptibilities to various antibacterial and antibiotic agents of bacterial strains isolated from urinary tract infections at 8 hospitals in Japan from July to October in 1986 are summarized as follows.<BR>1. Enterococcus faecalis was susceptible to sulfamethoxazole/trimethoprim (ST) and imipenem (IPM) with MIC90S of 0.78 and 1.56 μg/ml. Minocycline had the strongest activity against Staphylococcus aureus; the MICs for all strains tested were lower than 0.39 μg/ml. The MIC80S of dicloxacillin, and arbekacin (HBK) were 0.20 and 0.78 μg/ml, respectively. Among the cephems, the MIC80 of flomoxef was 25 μg/ml, whereas those of cefmenoxime (CMX) and cefotiam (CTM) were 50 μg/ml.<BR>2. Escherichia coli was most susceptible to ofloxacin (OFLX) among the oral antibacterial and antibiotic agents tested. OFLX showed the minimum inhibitory concentration against 90% (MIC90) of the 274 strains of E. coli tested to be lower than 0.10 μg/ml. The antibacterial activities of the third generation cephems such as CMX and latamoxef (LMOX) were the strongest among the injectable antibiotics tested. The MIC90S of CMX and LMOX were lower than 0.10 and 0.20 μg/ml, respectively. CTM and cefmetazole, the second generation cephems, were also highly active against E. coli with MIC90S of 0.39 and 1.56 μg/ml, respectively.<BR>3. Among the oral antibacterial and antibiotic agents tested, OFLX was the most active against Klebsiella pneumoniae. Its MIC90 was 0.78 μg/ml. Among the injectable antibiotics tested, CMX was the strongest with an MIC90 of 0.20 μg/ml; MIC90 of CTM and LMOX were 0.39 μg/ml.<BR>4. The tested antibacterial and antibiotic agents were generally less active against Citrobacter freundii than against other bacteria. The MIC80 of OFLX was 0.39 μg/ml. Gentamicin (GM) and ST were slightly active against C. freundii. Among the cephems, CMX had the MIC80 of 25 μg/ml.<BR>5. Enterobacter cloacae was less susceptible to the cephems tested. OFLX, GM, and mecillinam were active against this bacteria with MIC80S of 0.78, 0.78 and 1.56 μg/ml, respectively.<BR>6. Among the oral antibacterial and antibiotic agents and penicillins examined, piperacillin (PIPC) was the most active against Proteus mirabilis. Its MIC90 was 0.39 μg/ml. Those of sulbenicillin, cefaclor, ampicillin, OFLX, and ST were 0.78, 0.78, 1.56, 3.13 and 3.13 μg/ml, respectively. CMX was highly active against P. mirabilis with an MIC90 of ≤0.10 μg/ml; LMOX followed with an MIC90 of 0.20 μg/ml among the injectable antibiotics tested. CTM was also active against this bacterium; the MIC90 was 0.39 μg/ml.<BR>7. The antibacterial and antibiotic agents were generally only slightly active against Proteus vulgaris. The MIC80S of LMOX and CMX were 0.78 and 6.25 μg/ml, respectively.<BR>8. Morganella morganii was only weakly susceptible to antibacterial and antibiotic agents except the third generation cephalosporins. The MIC80S of CMX and LMOX were 0.78 μg/ml.<BR>9. The antibacterial and antibiotic agents were generally less active against Serratia marcescens than against other bacteria. The MIC80S of OFLX and CMX were 12.5 and 25 μg/ml, respectively.<BR>10. Pseudomonas aeruginosa was isolated frequently from urinary tract infections. Ciprofloxacin (CPFX) and norfloxacin (NFLX), new quinolones, were highly active against this bacterium with MIC50S of 0.20 and 0.78 μg/ml, respectively. The MIC50S of cefsulodin, IPM, ceftazidime, and tobramycin were all 1.56 μg/ml and those of PIPC, cefoperazone, carumonam and various aminoglycosides, such as micronomicin, dibekacin, sisomicin, GM and HBK, ranged from 3.13 μg/ml to 6.25 μg/ml.

Journal

Details 詳細情報について

  • CRID
    1390001205495095680
  • NII Article ID
    130004394893
  • DOI
    10.11553/antibiotics1968b.42.2141
  • COI
    1:STN:280:DyaK3c7ht1OqsQ%3D%3D
  • ISSN
    21865477
    03682781
  • PubMed
    2691714
  • Text Lang
    ja
  • Data Source
    • JaLC
    • PubMed
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top